Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization
Precigen, Inc. (NASDAQ:PGEN) is a biotechnology company developing precision genetic medicines for oncology, infectious diseases, and rare conditions.
Precigen Inc. (PGEN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Patient Capital Management Samantha Mclemore | 16,268,741 | $23,101,613 | -7% | 1.04% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 11,276,000 | $16,011,920 | 0.03% | |
| 3. | Iridian Asset Management David Cohen And Harold Levy | 4,278,662 | $6,075,700 | -7% | 2.1% |
| 4. | Parkman Healthcare Partners Greg Martinez | 1,542,823 | $2,190,809 | -52% | 0.25% |
| 5. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 1,438,463 | $2,042,614 | -49% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.40 | 2,000 | $6,800.00 | 405,959 | 2025-09-26 | Filing | |
| $3.58 | 6,000 | $21,480.00 | 65,031 | 2025-09-29 | Filing | |
| $3.42 | 2,932 | $10,027.44 | 468,626 | 2025-09-26 | Filing | |
| $3.62 | 8,284 | $29,988.08 | 465,694 | 2025-09-25 | Filing | |
| $4.60 | 15,000 | $69,000.00 | 217,841 | 2025-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.38 | 106,837 | $361,109.06 | 346,070 | 2025-09-30 | Filing | |
| $3.60 | 67,523 | $243,082.80 | 452,907 | 2025-09-29 | Filing | |
| $3.41 | 1,809,667 | $6,170,964.47 | 14,597,161 | 2025-09-30 | Filing | |
| $3.68 | 3,596,892 | $13,236,562.56 | 8,520,537 | 2025-09-19 | Filing | |
| $3.86 | 1,403,360 | $5,416,969.60 | 12,117,429 | 2025-09-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 134,226 | $441,604 | 0.04% | |
| 2. | 28,985 | $101,158 | 0% | |
| 3. | 28,231 | $92,880 | 0% | |
| 4. | 20,000 | $65,800 | 0.04% | |
| 5. | 18,217 | $59,934 | 0% |
News See All
15 Best Biotech Penny Stocks to Invest in Right Now
Jared Holz, the healthcare strategist for Mizuho, spoke on CNBC's "Closing Bell Overtime" in July on whether the biotech industry is ready for a breakthrough.
Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization
Precigen, Inc. (NASDAQ:PGEN) is one of the best healthcare penny stocks to buy now.
11 Best Healthcare Penny Stocks to Buy Now
The US healthcare sector is one of the biggest in the world, with spending expected to reach $5.3 trillion this year.
Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS
Precigen, Inc. (NASDAQ:PGEN) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 3, Precigen, Inc.
12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds
On September 12, Franklin Templeton released its research on active U.S. small-cap management.
Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism
Precigen Inc. (NASDAQ:PGEN) is one of the best multibagger stocks to invest in right now.
15 Best Multibagger Stocks to Invest in Right Now
Just as a single diamond can outshine a handful of pebbles, a well-chosen multibagger can transform an ordinary portfolio into an extraordinary one.
Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN)
Precigen, Inc. (NASDAQ:PGEN) is one of the must-buy penny stocks to invest in. On August 19, Cantor Fitzgerald reaffirmed its “Overweight” rating on Precigen stock.
10 Must-Buy Penny Stocks to Invest In
According to the LSEG 2025 Mid-Year Outlook, small-cap earnings are projected to grow 40.8% in 2025, compared to 8.8% for the S&P 500.
Hedge Fund Resource Center Billionaire Hedge Funds
